LifeMatrix develops a unique bio-engineering technology to grow human replacement tissues in the laboratory as next generation implants for the treatment of cardiovascular diseases.
LifeMatrix Technologies AG, is a pre-revenue, high-tech startup company spun out of the Institute for Regenerative Medicine (University of Zurich).
Our team combines world leading science in cardiovascular tissue engineering with in-depth entrepreneurial expertise in medical biomimetic device development.
Press & News
The Pionierpreis is considered one of the most important innovation prizes in Switzerland and a significant award for young companies.
Our CEO, Maximilian Emmert gives an interview in the EACTS News about his experience winning the Techno Collage Innovation Award.
LifeMatrix wins CHF 150,000 to develop groundbreaking biomimetic implants designed to grow and regenerate with patients.
LifeMatrix has been chosen by a jury of investors into the Swiss National Startup Team for Venture Leaders Life Sciences 2020 from over 60 applicants.
Medical Device Network
GlobalData: LifeMatrix set to disrupt cardiovascular implant market.
Diagnostic and Interventional Cardiology
Tissue Engineering Will Disrupt Cardiovascular Implant Market.
Biba Medtech Insights
Interview with Maximilian Emmert about the problems of transcatheter aortic valve implantation and how LifeMatrix could be the solution.
Biomimetic Solutions for Life
Award winning technology
Active in the field of biomimetic implants, LifeMatrix develops human cell derived, off-the-shelf available tissue engineered implants, which transform into living tissue after implantation and have the capacity to grow and regenerate with the patient.
The award winning technology is the result of multiple national and international research grants and is backed by more than 20 years of research with over 100 peer-reviewed publications.
Extensive preclinical (animal) studies demonstrated safety and efficacy and allow the technology to be translated in to clinical application.